Search Results - "Fishkin, Paul A. S."

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas by Major, Ajay, Kline, Justin, Karrison, Theodore G., Fishkin, Paul A. S., Kimball, Amy S., Petrich, Adam M., Nattam, Sreenivasa, Rao, Krishna, Sleckman, Bethany G., Cohen, Kenneth, Besien, Koen van, Rapoport, Aaron P., Smith, Sonali M.

“…The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus…”
Get full text

Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction by Choong, Nicholas W., Mauer, Ann M., Haraf, Daniel C., Ferguson, Mark K., Sandler, Alan B., Kesler, Kenneth A., Fishkin, Paul A. S., Ansari, Rafat H., Wade, James, Krauss, Stuart A., Sciortino, David F., Posner, Mitchell C., Kocherginsky, Masha, Hoffman, Philip C., Szeto, Livia, Vokes, Everett E.

“…We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer. Untreated stage II–IVa esophageal cancer…”
Get full text

Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group by Inwards, David J., Fishkin, Paul A. S., Hillman, David W., Brown, David W., Ansell, Stephen M., Kurtin, Paul J., Fonseca, Rafael, Morton, Roscoe F., Veeder, Michael H., Witzig, Thomas E.

“…BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL)…”
Get full text

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial by Tan, Winston W, Allred, Jacob B, Salim, Muhammad, Flynn, Patrick, Fishkin, Paul A.S, Stella, Philip J, Wiesenfeld, Martin, Bernath, Albert M, Fitch, Tom R, Perez, Edith A

“…Micro-Abstract This is a phase II study of vinorelbine, capecitabine, and trastuzumab in combination as first-line or second-line treatment of human epidermal…”
Get full text

Utility of flow cytometry immunophenotyping for the diagnosis and classification of lymphoma in community hospital clinical needle aspiration/biopsies by Siebert, J D, Weeks, L M, List, L W, Kugler, J W, Knost, J A, Fishkin, P A, Goergen, M H

“…Flow cytometry immunophenotyping (FC) of needle aspiration/biopsy (NAB) samples has been reported to be useful for the diagnosis and classification of lymphoma…”
Get full text

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma by Kahl, Brad S., Hong, Fangxin, Peterson, Christopher, Swinnen, Lode J., Habermann, Thomas M., Schuster, Stephen J, Weiss, Matthias, Fishkin, Paul A S, Ehmann, W. Christopher, Fenske, Timothy S., Williams, Michael E.

“…E4402 was a randomized phase III study comparing two different rituximab dosing strategies for patients with previously untreated, low tumor burden follicular…”
Get full text

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas by Major, Ajay, Kline, Justin, Karrison, Theodore G., Fishkin, Paul A S, Kimball, Amy S, Petrich, Adam M, Nattam, Sreenivasa, Sleckman, Bethany G, Cohen, Kenneth, van Besien, Koen, Rapoport, Aaron P., Smith, Sonali M.

“…Background Targeting the PI3K/Akt/mTOR axis in relapsed lymphomas is of interest based on constitutive activation in many lymphoma subtypes, and has had…”
Get full text

A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) by Szmulewitz, Russell Zelig, Ibraheem, Abiola Falilat, Peer, Cody J., Figg, William Douglas, Carthon, Bradley Curtis, Kozloff, Mark, Harvey, Donald, Fishkin, Paul A. S., Yong, Wei Peng, Chiong, Edmund, Nabhan, Chadi, O'Donnell, Peter H., Stadler, Walter Michael, Ratain, Mark J.

“…Abstract only 176 Background: AA is a standard of care for the treatment of metastatic CRPC, with an approximate retail cost of $8000/month. Despite a large…”
Get full text

Dynamic contrast enhanced-MRI (DCE-MRI) as a pharmacodynamic biomarker for pazopanib (PZ) in metastatic renal carcinoma (RC) by Sweis, Randy F., Medved, Milica, Towey, Shannon, Karczmar, Greg S., Oto, Aytekin, Szmulewitz, Russell Zelig, O'Donnell, Peter H., Fishkin, Paul A. S., Stadler, Walter Michael

“…Abstract only…”
Get full text

Evaluation of chemotherapy within last two weeks of life: Patterns of care by Thomas, Sachdev P., Rice, Michele A., Ho, Timmy-Tai A, Heard, Bridgette, Harper, Jamie, Fishkin, Paul A. S.

“…Abstract only e17590 Background: The discontinuation of chemotherapy within the last two weeks of life is a vital Quality Oncology Practice Initiative (QOPI)…”
Get full text

Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032 by INGLE, James N, SUMAN, Vera J, ROWLAND, Kendrith M, MIRCHANDANI, Deepu, BERNATH, Albert M, CAMORIANO, John K, FISLIKIN, Paul A. S, NIKCEVICH, Daniel A, PEREZ, Edith A

“…Fulvestrant is an antiestrogen that leads to estrogen receptor degradation and has demonstrated efficacy in breast cancer patients who have had disease…”
Get full text

Comparison of lymphoid neoplasm classification : A blinded study between a community and an academic setting by SIEBERT, James D, HARVEY, Leigh Anne C, FISHKIN, Paul A. S, KNOST, James A, EHSAN, Aamir, SMIR, Bassam N, CRAIG, Fiona E

“…The revised European-American classification of lymphoid neoplasms has been reported as reproducible among expert pathologists and feasible in a community…”
Get full text

Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification by SIEBERT, J. D, MULVANEY, D. A, POTTER, K. L, FISHKIN, P. A. S, GEOFFROY, F. J

“…Relative frequencies for common subtypes in the revised European-American classification of lymphoid neoplasms (REAL classification) have been reported. We…”
Get full text